NCT04664829 2025-09-23
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
National Cancer Centre, Singapore
Phase 1 Completed
Clinical Trials
6 trialsNCT03323658 2023-01-10
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01134341 2019-12-18
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Phase 1 Completed
NCT00316030 2016-06-08
Study of Bexarotene in Patients With Acute Myeloid Leukemia
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01001143 2014-07-29
AML
Washington University School of Medicine
Phase 1 Completed
NCT00055991 2013-02-05
Bexarotene in Preventing Breast Cancer in Women at Genetic Risk
Baylor Breast Care Center
Phase 1 Completed